Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022
21 oct. 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Moderna exercises option to license proprietary targeting technology from Autolus
12 oct. 2022 07h00 HE
|
Autolus Therapeutics plc
- Option exercised on undisclosed immune-oncology target following evaluation period by Moderna - - Autolus receives option exercise fee, with potential for development milestone payments plus...
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
04 oct. 2022 07h00 HE
|
Autolus Therapeutics plc
- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option...
mRNA Cancer Therapies Patent Landscape 2022: Featuring BioNTech, Moderna, Novartis, Sanofi & Others
04 oct. 2022 04h03 HE
|
Research and Markets
Dublin, Oct. 04, 2022 (GLOBE NEWSWIRE) -- The "mRNA Cancer Therapies Patent Landscape 2022" report has been added to ResearchAndMarkets.com's offering. For nearly three decades, extensive efforts...
Monthly information on share capital and company voting rights
19 sept. 2022 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal...
Global and China Passenger Car T-Box Market Report 2022-2025 Featuring 29 Major Chinese Vendors & 8 Major Global Vendors
05 sept. 2022 07h38 HE
|
Research and Markets
Dublin, Sept. 05, 2022 (GLOBE NEWSWIRE) -- The "Global and China Passenger Car T-Box Market Report, 2022" report has been added to ResearchAndMarkets.com's offering. Passenger car T-BOX research:...
Monthly information on share capital and company voting rights
22 août 2022 16h30 HE
|
Cellectis Inc.
NEW YORK, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of...
Autolus Therapeutics Reports Second Quarter 2022 Financial Results and Operational Progress
04 août 2022 07h00 HE
|
Autolus Therapeutics plc
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Global CAR-T Therapy Market Report 2022-2026 & 2031: Focus on Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA
03 août 2022 06h03 HE
|
Research and Markets
Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) -- The "CAR-T Therapy Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global CAR-T therapy market is expected to...
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
21 juil. 2022 07h54 HE
|
Autolus Therapeutics plc
In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version LONDON,...